`
`EXHIBIT C
`
`
`
`
`
`
`
`
`2022-38664
`
`No.
`
`6/28/2022 12:54 PM
`Marilyn Burgess - District Clerk Harris County
`Envelope No. 65843382
`By: Carolina Salgado
`Filed: 6/28/2022 12:54 PM
`
`RICKY MARSHALL,
`Plaintiff
`
`V.
`
`MEDTRONIC, INC.
`Defendant
`
`~
`~
`
`~
`
`IN THE DISTRICT COURT OF
`
`HARRIS COUNTY, TEXAS
`
`11 th
`
`JUDICIAL DISTRICT
`
`PLAINTIFF'S ORIGINAL PETITION
`
`TO THE HONORABLE JUDGE OF SAID COURT:
`
`COMES NOW, Ricky Marshall, plaintiff, complaining of Medtronic, Inc., defendant, and
`
`for cause of action would show as follows:
`
`I.
`
`This case should be governed in accordance with the Discovery Control Plan found in Rule
`
`190 of the Texas Rules of Civil Procedure (Level 3).
`
`II.
`
`Ricky Marshall ("Marshall'~ is an individual residing in Houston, Harris County, Texas.
`
`Medtronic, Inc., a subsidiary of Medtronic PLC ("Medtronic"), is a foreign eorporation with
`
`its principle operational offices located at 710 Medtronic Parkway, Minneapolis, Minnesota 55432-
`
`5604. Medtronic is and has been doing business in the State of Texas. Medtronic may be served
`
`with process through its agent for process, Corporation Service Company d/b/a CSC-Lawyers
`
`Incorporating Service Company 211 E. 7th Street, Suite 620, Austin, TX 78701-3136 USA.
`
`Marshall seeks to recover damages he has sustained due to a defective LVAD pump system,
`
`sometimes referred to as the HeartWare HVAD device ("HeartWare device"), manufactured and
`
`sold by Medtronic that was implanted in Marshall's chest by Saram Nathan, M.D. at Memorial
`
`Hermann Hospital, Houston, Harris County, Texas, on June 4, 2020. Marshall was discharged from
`
`
`
`
`
`Memorial Hermann Hospital on June 29, 2020. 1Vlarshall underwent this implant surgery due to
`
`end-stage heart failure from which he was suffering. He understood at the time of his surgery the
`
`HeartWare device would assist his own circulatory system by pumping blood from his damaged
`
`heart. The Heartware device would keep Marshall alive until he was approved for and could
`
`undergo a heart transplant procedure.
`
`~
`
`Medtronic abruptly pulled its HeartWare device from the market in late May, 2021, less than
`
`a year after the device was implanted in Marshall's chest. The action undertaken by Medtronic came
`
`as a result of numerous Class I recalls and reports of patient injuries and deaths associated with the
`
`device. Prior to the implant surgery involving Marshall, there was great concern with the Medtronic
`
`HeartWare device regarding ongoing failures and a"growing body of observational clinical
`
`comparisons indicating a higher frequency of neurological adverse events, including stroke, and
`
`mortality with the Heartware device as compared to other circulatory support devices available to
`
`patients." At the time Medtronic stopped selling the HeartWare device, approximately 4,000
`
`patients had the device impla.nted, including Marshall. Moreover, Medtronic advised against elective
`
`explants of the HeartWare device due to potential health risks to the patient. A patient such as
`
`Marshall was as likely to die from removal of the HeartWare device as he was if the device remained
`
`in his body.
`
`V.
`
`Marshall seeks damages from Medtronic, under two theories of recovery, namely:
`
`(1)
`
`Products liability based upon:
`
`(a)
`
`(b)
`
`(c)
`
`Manufacturing defect;
`
`Design defect; and
`
`Marketing defect.
`-2-
`
`
`
`
`
`(2)
`
`Negligence in the marketing and the manufacturing of the HeartWare
`device manufactured and sold by Medtronic, which is the subject of
`this lawsuit; additionally, invoking the negligence doctrine of res psa
`loquitur.
`
`VI.
`
`When it is alleged that Medtronic committed an act or practice, or by omission failed to act,
`
`it is meant that Medtronie acted or failed to act by and through its agents, servants and employees
`
`whose acts or omissions were within the scope of their authority or employment.
`
`The cause of action giving rise to this lawsuit, that is, the claims for damages for the injuries
`
`sustained by the plaintiff as a result of Medtronic's wrongdoing, arose in Harris County, Texas.
`
`Medtronic was at the time of this occurrence and was the major designer, manufactorer and
`
`marketer of the HeartWare device. Additionally, at all times pertinent hereto, Medtronic was a
`
`merchant with respect to the HeartWare device within the meaning of TEX. BUS. & COM. CODE
`
`5 2.314. Medtronic was, at all times pertinent hereto, the marketer and seller of the HeartWare
`
`device.
`
`W".
`
`Medtronic's decision to pull the HeartWare device from the market followed a series of
`
`Class I recalls, including three in 2021 alone, resulting in reports of 91 injuries and 15 deaths of
`
`patients with the implanted device. The Federal Drug Administration (FDA) advised healthcare
`
`providers in late May, 2021, to cease new implants of the HeartWare device system, indicating that
`
`Medtronic had "received over 100 complaints involving delay or failure to restart of the HeartWare
`
`device, including reports of 14 patient deaths and 13 cases where an explant was necessary."
`
`-3-
`
`
`
`
`
`Medtronic had acquired the HeartWare device was part of its $1.1 billion acquisition of
`
`HeartWare International in 2016. The device was intended to help patients suffering from heart
`
`failure pumping blood through their bodies. The system, wbich included an implantable pump and
`
`non-implantable components, is a Class III medical device, meaning it constitutes a high risk and
`
`can pose a significant risk of injury to patients.
`
`Since the HeartWare device received premarket approval in November, 2012, the FDA has
`
`issued 13 Class I recalls involving multiple parts and components of the pump.
`
`Issues and
`
`malfunctions ranged from devices failing to restart to the company needing to update instructions
`
`for use and patient manuals. While some recalls predate Medtronic's acquisition, nine Class I recalls
`
`have come since Medtronic bought HeartWare.
`
`Along with numerous recalls, the HeartWare device has received thousands of reports of
`
`patient injuries, deaths and device malfunctions in the FDA's Manufacturer and User Facility Device
`
`Experience (MAUDE) database. An analysis of MAUDE data by the watchdog group ECRI
`
`showed Medtronic's HeartWare device had a higher rate of device malfunction than comparable
`
`devices marketed by rival companies.
`
`0:4
`
`Marshall's HeartWare device was not intended to be defective and cause unanticipated or
`
`unnecessary delays or failures to restart the pumping of blood. Such a defect was not intended to be
`
`part of the HVAD pump design or purpose. As a result, Marshall has sustained both physical and
`
`mental damages, particularly the mental stress of having an implanted device that is very unreliable
`
`and cannot be removed due to the lethal risk of expla.ntation.
`
`XI.
`
`Medtronic has removed the HeartWare device from the market due to its use being
`
`associated with increased risks of mortality. Patients, such as Marshall, who have been implanted
`-4-
`
`
`
`
`
`with the device have increased morbidity, with anxiety, depression, and even post-traumatic stress
`
`response due to the device being implanted in their bodies. These consequences can lead to further
`
`fanctional decline in the patient, such as Marshall, and a decreased quality of life.
`
`The HeartWare device, as manufactured, designed and marketed by Medtronic, is defective
`
`and unsafe.
`
`The defect in the manner in which the HeartWare device was designed or manufactured at
`
`the time it left the possession of Medtronic rendered the product unreasonably dangerous and made
`
`it dangerous to an extent beyond which would be contemplated by the ordinary user of the product,
`
`including this plaintiff, with the ordinary knowledge common to the community as to the product's
`
`characteristics.
`
`There was a design defect caused by Medtronic at the time the HeartWare device left the
`
`possession of Medtronic that rendered the product unreasonably dangerous as designed, taking into
`
`consideration the utility of the product and the risk involved in its use.
`
`The design and manufactu.ring defects in the HeartWare device that are involved in this
`
`lawsuit existed in said product while it was in the hands of Medtronic, and such defect rendered said
`
`product unfit for the ordinary purposes for which it was to have been used by the ultimate user,
`
`including this plaintiff, because of a lack of something necessary for adequacy.
`
`There was a defect in the marketing of HeartWare device caused by Medtronic at the time it
`
`left the possession of Medtronic in that there was a failure by Medtronic to give adequate warnings
`
`of said product's dangers that were known by Medtronic or by the application o£ reasonably
`
`developed skill and foresight should have been known by Medtronic, or there was a failure by
`
`1Vledtronic to give adequate instructions to avoid such dangers, which failures rendered the
`
`HeartWare device unreasonably dangerous as marketed.
`-5-
`
`
`
`
`
`The foregoing defects, taken together, separately or in combination, constituted a producing
`
`or proximate cause or causes of the plaintiffs damages.
`
`Marshall did not and in the exercise of reasonable diligence could not have discovered the
`
`defects in design, manufacture and/or marketing of the HeartWare device HVAD pump system
`
`prior to the date it was implanted in his chest and the resulting injuries he sustained. Neither did he
`
`discover nor in the exercise of reasonable diligence could he have discovered the negligence of
`
`Medtronic in the design, manufacturing and/or marketing of the HeartWare device prior to the date
`
`product was implanted in his chest and the resulting injuries he sustained.
`
`~~I
`
`Medtronic was negligent in designing, manufacturing and marketing the HeartWare device in
`
`question in the following respects:
`
`(1)
`
`(2)
`
`Medtronic was negligent in failing to properly design or compose the
`HeartWare device; and
`
`Medtronic was negligent in offering the HeartWare device for sale to the
`general public without warning the end users of the dangers associated with
`the HeartWare device.
`
`Marshall cannot more specifically allege the acts and/or omissions of negligence in the
`
`manufacturing and/or design of the HeartWare device in question for the reasons that the facts in
`
`that regard are peculiarly within the knowledge of Medtronic. In this connection, Marshall would
`
`show that the design and manufacturing of the HeartWare device was within the exclusive
`
`possession a.nd control of Medtronic. Marshall had no means of ascertaining the method and
`
`manner in which the HeartWare device was designed, tested and manufactured. The product was
`
`prescribed to and taken as recommended by plaintiff in the same condition it was in when it left the
`
`possession and control of Medtronic. The occurrence causing the injury to the plaintiff, as
`
`-6-
`
`
`
`
`
`described herein, was one which, in the ordinary course of events, would not have occurred without
`
`the negligence on the part of Medtronic in the design and/or manufacturing of the HeartWare
`
`device. Thus the plaintiff is entitled to invoke the negligence doctrine of res ipsa loquitur, thereby
`
`making Medtronic guilty of negligence in the design, manufacturing and marketing of the HeartWare
`
`device without further proof, which negligence was a proximate cause of the injuries and damages
`
`sustained by the plaintiff.
`
`XV.
`
`Marshall's damages exceed the jurisdictional limits of this Court. The plaintiff has been
`
`damaged in the following particulars, viz:
`
`a.
`
`b.
`
`C.
`
`d.
`
`e.
`
`f.
`
`g.
`
`h.
`
`i.
`
`Loss of wages in the past and future;
`
`Reasonable and necessary costs of inedical care and treatment including
`doctors, hospitals, nurses, medicine, and other services and supplies in the
`past;
`
`Reasonable and necessary costs of inedical care and treatment including
`doctors, hospitals, nurses, medicine, and other services and supplies that in
`all reasonable probability plaintiff will suffer in the future;
`
`Physical pain suffered by the plaintiff in the past;
`
`Physical pain which the plaintiff will in all reasonable probability suffer in the
`future;
`
`Mental anguish suffered by the plaintiff in the past;
`
`Mental anguish which the plaintiff will in all reasonable probability suffer in
`the future;
`
`Past impairment suffered by the plaintiff;
`
`Future impairment that will be suffered by the plaintiff in all reasonably
`probability;
`
`Past disfigurement suffered by the plaintiff; and
`
`k.
`
`Future disfigarement that will be suffered by the plaintiff.
`
`-7-
`
`
`
`
`
`As a result of such particulars, Marshall has been damaged in an amount in excess of the minimum
`
`jurisdictional limits of this Court.
`
`Marshall is entitled to recover his actual damages, prejudgment interest, and exemplary or
`
`punitive damages as a result of the above allegations of liability and damages. The assessment of any
`
`exemplary and/or punitive damages should include evidence of and consideration of reasonable
`
`attorney's fees.
`
`WHEREFORE, PREMISES CONSIDERED, Ricky Marshall, plaintiff, requests Medtronic,
`
`Inc., defendant, be cited to appear and a.nswer, and that upon final trial, they have:
`
`a.
`
`b.
`
`C.
`
`d.
`
`Judgment against Medtronic Inc. for ONE MILLION AND NO/100
`DOLLARS ($1,000,000.00);
`
`Pre-judgment and post-judgment interest on damages assessed against the
`defendant at the prescribed legal rate;
`
`Costs of court; and
`
`Such other and further relief, at law or in equity, to which they may be justly
`entitled.
`
`Respectfully submitted,
`
`THE TRIMBLE FIRM, P.L.L.C.
`
`/Q/ DaQe Z. ?ZuscZee
`
`By
`
`Dale L. Trimble
`State Bar No. 20222650
`209 Simonton Street
`Conroe, Texas 77301
`Telephone:
`(936) 441-3456
`(936) 539-3457
`(936) 539-3464
`Telecopier:
`Email: eservice(a7trimblefirm.com
`Counsel for Plaintiff, Ricky Marshall
`
`-8-
`
`